Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial  William J. Sandborn, Stefan Schreiber, Brian G. Feagan, Paul Rutgeerts, Ziad H. Younes, Ralph Bloomfield, Geoffroy Coteur, Juan Pablo Guzman, Geert R. D'Haens  Clinical Gastroenterology and Hepatology  Volume 9, Issue 8, Pages 670-678.e3 (August 2011) DOI: 10.1016/j.cgh.2011.04.031 Copyright © 2011 AGA Institute Terms and Conditions

Figure 1 (A) Clinical remission rate (CDAI score ≤150) at weeks 2, 4, and 6: ITT population. (B) Clinical remission rate (CDAI score ≤150) at week 6 by CRP cutoff: ITT population. Lower limit of quantification for CRP is <3 mg/L. (C) Clinical remission rate at week 6 stratified by both baseline CRP concentration (<5 mg/L vs ≥5 mg/L) and location of disease (terminal ileum, ileocolon, colon): ITT population. GI, gastrointestinal. Clinical Gastroenterology and Hepatology 2011 9, 670-678.e3DOI: (10.1016/j.cgh.2011.04.031) Copyright © 2011 AGA Institute Terms and Conditions

Figure 2 Distribution of CRP concentrations at week 0 by treatment group: ITT population. Clinical Gastroenterology and Hepatology 2011 9, 670-678.e3DOI: (10.1016/j.cgh.2011.04.031) Copyright © 2011 AGA Institute Terms and Conditions

Supplementary Figure 1 Disposition of the patients. *One patient was randomized but received no treatment. Clinical Gastroenterology and Hepatology 2011 9, 670-678.e3DOI: (10.1016/j.cgh.2011.04.031) Copyright © 2011 AGA Institute Terms and Conditions

Supplementary Figure 2 Summary of odds ratios for the proportion of patients achieving clinical remission at week 6 for certolizumab pegol (CZP) vs placebo by prespecified subgroups: ITT population. For disease location, the number of patients where the investigator reported upper gastrointestinal disease was too small to allow an odds ratio and confidence interval to be derived. CI, confidence interval; BMI, body mass index; IM, immunosuppressant; CS, corticosteroid. Clinical Gastroenterology and Hepatology 2011 9, 670-678.e3DOI: (10.1016/j.cgh.2011.04.031) Copyright © 2011 AGA Institute Terms and Conditions

Supplementary Figure 3 Summary of odds ratios for the proportion of patients achieving clinical remission at week 6 for certolizumab pegol (CZP) vs placebo by country and geographic region prespecified subgroups: ITT population. CI, confidence interval. Clinical Gastroenterology and Hepatology 2011 9, 670-678.e3DOI: (10.1016/j.cgh.2011.04.031) Copyright © 2011 AGA Institute Terms and Conditions